-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Roche announced to reduce the price of the breast cancer drug enmetrastuzumab by as much as 52%, of which the 100mg/bottle dosage form was reduced from 19,282.
00 yuan to 9,200 yuan, and the 160mg/bottle dosage form was reduced from 27,632.
04 yuan to 13,184.
05 yuan.
Bringing good news to the vast number of breast cancer patients in China
.
Breast cancer is a gynecological tumor disease that seriously threatens women's health
.
There are many breast cancer patients in China, and there are 400,000 new breast cancer patients every year
.
Among them, HER2-positive breast cancer accounts for about 20% to 25% of all breast cancers, and is a subtype of breast cancer with poor prognosis, which seriously affects the physical and mental health of patients
.
With the continuous breakthrough in the field of anti-HER2 therapy, HER2-positive breast cancer patients are embracing more and more targeted drugs and adjuvant therapy options, but overall there are still large unmet clinical needs
.
As a HER2-targeting antibody-drug conjugate, enme-trastuzumab was developed by Roche Pharmaceuticals.
Enme-trastuzumab inhibits HER2 receptor signaling, exerts antibody-dependent cell-mediated cytotoxicity, and inhibits excessive HER2 receptor signaling.
Shedding of the HER2 extracellular domain in HER2-expressing human breast cancer cells
.
The product was approved by the FDA in February 2013 for the treatment of patients with HER2-positive metastatic breast cancer who have failed trastuzumab and paclitaxel chemotherapy
.
In China, the product was approved by the China Food and Drug Administration in January 2020 for the use of HER2-positive early breast cancer with residual invasive lesions after receiving taxanes combined with trastuzumab-based neoadjuvant therapy adjuvant therapy for patients
.
In June 2021, trastuzumab was approved for the second indication in China, for the monotherapy of HER2-positive, unresectable locally advanced or metastatic disease treated with taxanes and trastuzumab.
breast cancer patients
.
As the first antibody-conjugated drug (ADC) marketed in the field of breast cancer in China, this product has brought good news to the majority of patients
.
"Chinese Anti-Cancer Association Guidelines and Specifications for Breast Cancer Diagnosis and Treatment (2021 Edition)" has included this product in adjuvant therapy after neoadjuvant therapy for HER2-positive breast cancer"
.
However, monoclonal antibody products are often expensive, and many patients' families cannot bear the heavy burden of drug costs
.
In order to reduce the burden on patients and families, the patient assistance program has been launched in China as early as after the listing of Enme-trastuzumab
.
In 2021, the product failed to be included in medical insurance through negotiation, but the industry pointed out that Roche's price reduction this time is close to the average price reduction in medical insurance negotiations
.
In fact, not only Roche, but also Pfizer’s new breast cancer drug Aiboxin, which was not covered by medical insurance, also made a decision to reduce the price by 54%, and the price per bottle dropped from 29,799 yuan to 13,667 yuan
.
At the same time, Pfizer also adjusted its patient assistance program, phasing out charitable drug donations for low-income and low-income patients
.
Behind the price cuts made by many multinational pharmaceutical companies, the industry generally said that the price war for HER-2-positive breast cancer drugs has actually started
.
At present, a large number of domestic pharmaceutical companies have entered the market, including Hengrui, Sihuan Pharmaceutical, Luye Pharmaceutical, etc.
, and the market competition is already very fierce
.
Industry analysts believe that with the advancement of national medical insurance negotiations and the normalization of centralized procurement, the competition in the domestic pharmaceutical market will become more intense, which will force multinational pharmaceutical companies to adjust their focus and gradually change their business models.
There will be more and more pharmaceutical companies in the future, and the price cuts will be relatively large
.
This may be good news for the majority of breast cancer patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
00 yuan to 9,200 yuan, and the 160mg/bottle dosage form was reduced from 27,632.
04 yuan to 13,184.
05 yuan.
Bringing good news to the vast number of breast cancer patients in China
.
Breast cancer is a gynecological tumor disease that seriously threatens women's health
.
There are many breast cancer patients in China, and there are 400,000 new breast cancer patients every year
.
Among them, HER2-positive breast cancer accounts for about 20% to 25% of all breast cancers, and is a subtype of breast cancer with poor prognosis, which seriously affects the physical and mental health of patients
.
With the continuous breakthrough in the field of anti-HER2 therapy, HER2-positive breast cancer patients are embracing more and more targeted drugs and adjuvant therapy options, but overall there are still large unmet clinical needs
.
As a HER2-targeting antibody-drug conjugate, enme-trastuzumab was developed by Roche Pharmaceuticals.
Enme-trastuzumab inhibits HER2 receptor signaling, exerts antibody-dependent cell-mediated cytotoxicity, and inhibits excessive HER2 receptor signaling.
Shedding of the HER2 extracellular domain in HER2-expressing human breast cancer cells
.
The product was approved by the FDA in February 2013 for the treatment of patients with HER2-positive metastatic breast cancer who have failed trastuzumab and paclitaxel chemotherapy
.
In China, the product was approved by the China Food and Drug Administration in January 2020 for the use of HER2-positive early breast cancer with residual invasive lesions after receiving taxanes combined with trastuzumab-based neoadjuvant therapy adjuvant therapy for patients
.
In June 2021, trastuzumab was approved for the second indication in China, for the monotherapy of HER2-positive, unresectable locally advanced or metastatic disease treated with taxanes and trastuzumab.
breast cancer patients
.
As the first antibody-conjugated drug (ADC) marketed in the field of breast cancer in China, this product has brought good news to the majority of patients
.
"Chinese Anti-Cancer Association Guidelines and Specifications for Breast Cancer Diagnosis and Treatment (2021 Edition)" has included this product in adjuvant therapy after neoadjuvant therapy for HER2-positive breast cancer"
.
However, monoclonal antibody products are often expensive, and many patients' families cannot bear the heavy burden of drug costs
.
In order to reduce the burden on patients and families, the patient assistance program has been launched in China as early as after the listing of Enme-trastuzumab
.
In 2021, the product failed to be included in medical insurance through negotiation, but the industry pointed out that Roche's price reduction this time is close to the average price reduction in medical insurance negotiations
.
In fact, not only Roche, but also Pfizer’s new breast cancer drug Aiboxin, which was not covered by medical insurance, also made a decision to reduce the price by 54%, and the price per bottle dropped from 29,799 yuan to 13,667 yuan
.
At the same time, Pfizer also adjusted its patient assistance program, phasing out charitable drug donations for low-income and low-income patients
.
Behind the price cuts made by many multinational pharmaceutical companies, the industry generally said that the price war for HER-2-positive breast cancer drugs has actually started
.
At present, a large number of domestic pharmaceutical companies have entered the market, including Hengrui, Sihuan Pharmaceutical, Luye Pharmaceutical, etc.
, and the market competition is already very fierce
.
Industry analysts believe that with the advancement of national medical insurance negotiations and the normalization of centralized procurement, the competition in the domestic pharmaceutical market will become more intense, which will force multinational pharmaceutical companies to adjust their focus and gradually change their business models.
There will be more and more pharmaceutical companies in the future, and the price cuts will be relatively large
.
This may be good news for the majority of breast cancer patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
